ASH 2024 – Paolo Ghia
Paolo Ghia delves into the ongoing debate between fixed-duration and continuous targeted therapies in CLL, focusing on their respective impacts on long-term survival outcomes. He highlights cellular mechanisms that enable MRD cells to survive despite BTK inhibition and shares his personal highlights from this year’s ASH conference, emphasizing those with the most significant impact on clinical practice.
